Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Federal Trade Commission
QuintilesIMS
Cantor Fitzgerald
Deloitte
Dow
Accenture
Cipla
Queensland Health
Express Scripts

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,975,690

« Back to Dashboard

Which drugs does patent 7,975,690 protect, and when does it expire?


Patent 7,975,690 protects ONZETRA XSAIL and is included in one NDA.

This patent has one hundred and forty-six patent family members in twenty-six countries.

Summary for Patent: 7,975,690

Title:Nasal devices
Abstract: The present invention relates to a nasal delivery device for and a method of delivering a substance, in particular one of a liquid, as a suspension or solution, or a powder containing a medicament, especially systemic or topical pharmaceuticals, or a vaccine to the nasal airway of a subject.
Inventor(s): Djupesland; Per Gisle (Olso, NO)
Assignee: OptiNose AS (Oslo, NO)
Application Number:10/480,582
Patent Claim Types:
see list of patent claims
Use; Delivery; Device; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYesYes► Subscribe► SubscribeY METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,975,690

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0114272.8Jun 12, 2001
PCT Information
PCT FiledJune 12, 2002PCT Application Number:PCT/IB02/03034
PCT Publication Date:January 03, 2003PCT Publication Number: WO03/000310

Non-Orange Book Patents for Patent: 7,975,690

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,841,337Breath-actuated nasal delivery device► Subscribe
9,468,727Nasal delivery► Subscribe
9,119,932Nasal delivery device► Subscribe
6,715,485 Nasal delivery device► Subscribe
8,522,778Nasal devices► Subscribe
9,205,208Nasal devices► Subscribe
8,555,877Nasal delivery device► Subscribe
7,543,581Nasal devices► Subscribe
9,072,857Nasal delivery device► Subscribe
7,740,014Nasal devices► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,975,690

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2364009► Subscribe
Canada2438977► Subscribe
Canada2450492► Subscribe
Canada2714072► Subscribe
Canada2953606► Subscribe
China1342093► Subscribe
China1217712► Subscribe
China1524001► Subscribe
China1525871► Subscribe
China100428966► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
US Army
Mallinckrodt
AstraZeneca
Cerilliant
Baxter
Boehringer Ingelheim
Argus Health
QuintilesIMS
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot